FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891945121> ?p ?o ?g. }

• W2891945121 endingPage "e181449" @default.
• W2891945121 startingPage "e181449" @default.
• W2891945121 abstract "<h3>Importance</h3> Latent hepatic<i>Plasmodium vivax</i>hypnozoites provoke repeated clinical attacks called relapses. Only primaquine phosphate kills hypnozoites, and its therapeutic activity may depend on naturally polymorphic cytochrome P450 2D6 isotype (CYP2D6) activity. <h3>Objective</h3> To examine the association of impaired<i>CYP2D6</i>genotypes and CYP2D6 metabolic phenotypes with therapeutic failure of directly observed high-dose primaquine treatment for<i>P vivax</i>malaria relapse. <h3>Design, Setting, and Participants</h3> Nested case-control study of patients who, in July 2014, completed a randomized clinical trial of directly observed primaquine treatment for radical cure of acute<i>P vivax</i>malaria in an area of Indonesia where reinfection during 1 year of posttreatment follow-up was improbable. A total of 177 of 180 patients with<i>P vivax</i>malaria completed the clinical trial of primaquine treatment to prevent relapse; 151 were eligible for recruitment as controls. After screening, 59 potential control individuals (no relapse) and 26 potential case patients (relapse) were considered, and 36 controls and 21 cases were enrolled. <h3>Exposures</h3> Cases and controls were exposed to<i>P vivax</i>malaria and primaquine therapy but had variable exposure to the enzymatic activity of CYP2D6, classified as impaired by a genotype-determined qualitative phenotype (poor or intermediate), genotype-determined activity score less than 1.5, or a log of the 24-hour pooled urine dextromethorphan-dextrorphan metabolic ratio greater than −1.0. <h3>Main Outcomes and Measures</h3> Unadjusted odds ratios (ORs) of relapse with impaired CYP2D6 metabolism determined by genotype or measured by urinary dextromethorphan-dextrorphan metabolic ratio. <h3>Results</h3> Among the 21 cases (mean [SD] age, 30.5 [6.3] years; all male) and 36 controls (mean [SD] age, 29.0 [3.6] years; all male), 6<i>CYP2D6</i>alleles (*1, *2, *4, *5, *10, and *41) occurred as 12 distinct genotypes, with model activity scores ranging from 0.0 to 2.0. Among 32 patients with genotypic activity scores of 1.0 or less, 18 had experienced relapse, whereas among the 25 with scores higher than 1.0, 3 had experienced relapse (OR, 9.4; 95% CI, 2.1-57.0;<i>P</i> = .001). When the log of the metabolic ratio of dextromethorphan-dextrorphan was −1.0 or less, only 1 of 18 patients experienced relapse, whereas above that threshold (consistent with low metabolic activity), 20 of 39 patients experienced relapse (OR, 18; 95% CI, 2.2-148.0;<i>P</i> = .007). <h3>Conclusions and Relevance</h3> Genotype-determined and directly measured impaired levels of CYP2D6 activity were associated with elevated risk of therapeutic failure. These findings suggest a natural variability in CYP2D6-dependent metabolism of primaquine as a key determinant of therapeutic efficacy against latent<i>P vivax</i>malaria." @default.
• W2891945121 created "2018-09-27" @default.
• W2891945121 creator A5003635603 @default.
• W2891945121 creator A5008762753 @default.
• W2891945121 creator A5011524515 @default.
• W2891945121 creator A5014594025 @default.
• W2891945121 creator A5020721525 @default.
• W2891945121 creator A5020987241 @default.
• W2891945121 creator A5030589035 @default.
• W2891945121 creator A5034219102 @default.
• W2891945121 creator A5038807888 @default.
• W2891945121 creator A5039482621 @default.
• W2891945121 creator A5047507055 @default.
• W2891945121 creator A5049540109 @default.
• W2891945121 creator A5058086526 @default.
• W2891945121 creator A5061309607 @default.
• W2891945121 creator A5062114143 @default.
• W2891945121 creator A5066080831 @default.
• W2891945121 creator A5067103432 @default.
• W2891945121 creator A5071652312 @default.
• W2891945121 creator A5080326501 @default.
• W2891945121 date "2018-08-31" @default.
• W2891945121 modified "2023-10-16" @default.
• W2891945121 title "Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent<i>Plasmodium vivax</i>Malaria" @default.
• W2891945121 cites W16807700 @default.
• W2891945121 cites W1839670086 @default.
• W2891945121 cites W1924088672 @default.
• W2891945121 cites W1950127504 @default.
• W2891945121 cites W196795570 @default.
• W2891945121 cites W1969834934 @default.
• W2891945121 cites W1984131408 @default.
• W2891945121 cites W1986157879 @default.
• W2891945121 cites W1988065177 @default.
• W2891945121 cites W2008825099 @default.
• W2891945121 cites W2013411967 @default.
• W2891945121 cites W2014303468 @default.
• W2891945121 cites W2035387023 @default.
• W2891945121 cites W2040554187 @default.
• W2891945121 cites W2055757784 @default.
• W2891945121 cites W2072894930 @default.
• W2891945121 cites W2093298914 @default.
• W2891945121 cites W2096415021 @default.
• W2891945121 cites W2104058573 @default.
• W2891945121 cites W2116272552 @default.
• W2891945121 cites W2134054893 @default.
• W2891945121 cites W2137935465 @default.
• W2891945121 cites W2137952006 @default.
• W2891945121 cites W2157582041 @default.
• W2891945121 cites W2159923524 @default.
• W2891945121 cites W2160756895 @default.
• W2891945121 cites W2199277501 @default.
• W2891945121 cites W2307122094 @default.
• W2891945121 cites W2462041221 @default.
• W2891945121 cites W2793635060 @default.
• W2891945121 cites W55861200 @default.
• W2891945121 doi "https://doi.org/10.1001/jamanetworkopen.2018.1449" @default.
• W2891945121 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6324265" @default.
• W2891945121 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30646129" @default.
• W2891945121 hasPublicationYear "2018" @default.
• W2891945121 type Work @default.
• W2891945121 sameAs 2891945121 @default.
• W2891945121 citedByCount "72" @default.
• W2891945121 countsByYear W28919451212018 @default.
• W2891945121 countsByYear W28919451212019 @default.
• W2891945121 countsByYear W28919451212020 @default.
• W2891945121 countsByYear W28919451212021 @default.
• W2891945121 countsByYear W28919451212022 @default.
• W2891945121 countsByYear W28919451212023 @default.
• W2891945121 crossrefType "journal-article" @default.
• W2891945121 hasAuthorship W2891945121A5003635603 @default.
• W2891945121 hasAuthorship W2891945121A5008762753 @default.
• W2891945121 hasAuthorship W2891945121A5011524515 @default.
• W2891945121 hasAuthorship W2891945121A5014594025 @default.
• W2891945121 hasAuthorship W2891945121A5020721525 @default.
• W2891945121 hasAuthorship W2891945121A5020987241 @default.
• W2891945121 hasAuthorship W2891945121A5030589035 @default.
• W2891945121 hasAuthorship W2891945121A5034219102 @default.
• W2891945121 hasAuthorship W2891945121A5038807888 @default.
• W2891945121 hasAuthorship W2891945121A5039482621 @default.
• W2891945121 hasAuthorship W2891945121A5047507055 @default.
• W2891945121 hasAuthorship W2891945121A5049540109 @default.
• W2891945121 hasAuthorship W2891945121A5058086526 @default.
• W2891945121 hasAuthorship W2891945121A5061309607 @default.
• W2891945121 hasAuthorship W2891945121A5062114143 @default.
• W2891945121 hasAuthorship W2891945121A5066080831 @default.
• W2891945121 hasAuthorship W2891945121A5067103432 @default.
• W2891945121 hasAuthorship W2891945121A5071652312 @default.
• W2891945121 hasAuthorship W2891945121A5080326501 @default.
• W2891945121 hasBestOaLocation W28919451211 @default.
• W2891945121 hasConcept C126322002 @default.
• W2891945121 hasConcept C203014093 @default.
• W2891945121 hasConcept C2776793103 @default.
• W2891945121 hasConcept C2777425658 @default.
• W2891945121 hasConcept C2778048844 @default.
• W2891945121 hasConcept C2778371730 @default.
• W2891945121 hasConcept C2779997623 @default.
• W2891945121 hasConcept C71924100 @default.
• W2891945121 hasConcept C98274493 @default.

• next